Volume 1 - Supplement Issue 1: Abstracts of International Tehran Breast Cancer Congress                   Multidiscip Cancer Investig 2017, 1 - Supplement Issue 1: Abstracts of International Tehran Breast Cancer Congress: 0-0 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tafti A, Shahani M, Mahmanzar M A, Khanabadi B, Shakeri J. CD44 as a Biomarker in the Early Detection of Breast Cancer. Multidiscip Cancer Investig 2017; 1
URL: http://mcijournal.com/article-1-109-en.html
Abstract:   (5780 Views)
Introduction: Due to the high prevalence of low-risk breast cancer (BC) and the side effects affecting families in Iran, related researches are necessary. BC is one of the main leading causes of death in women, causing 40,000 to 50,000 deaths per year. Therefore, the recognition of prognostic factors, biomarkers and preventive factors can be useful for selecting appropriate therapies and clinical decisions.
Materials and Methods: According to Keywords: Breast Cancer, Biomarkers, Early detection and cancer Stem cell that utilized the valid databases, such as: Scopus, NCBI and Elsevier. The papers collected and then was ranking based on appropriate criteria.
Results: In this study, according to key words in the field of Biomarkers involved in Breast Cancer 65 articles were selected. After completing the final analysis, 15 studies from other research more relevant to their subject, were assessed.
Conclusions: The heterogeneous and difficult nature of the BC is becoming a leading condition to define, in accordance with its growing incidence and poor. According to of Results, identify CD44 as a biomarker that is important in the early detection of Breast Cancer.
Full-Text [PDF 61 kb]   (1714 Downloads)    
Select article type: Original/Research Article | Subject: Materials Science and Nanomedicine
Received: 2017/10/28 | Accepted: 2017/10/28 | ePublished: 2017/10/28

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb